ESSA Pharma Inc. financial data

Symbol
EPIX on Nasdaq
Industry
Pharmaceutical Preparations
Location
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
September 30
Latest financial report
10-Q - Q4 2024 - Feb 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.52K % -26.7%
Debt-to-equity 3.09 % +41.9%
Return On Equity -24.6 % -41.4%
Return On Assets -23.9 % -40.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.4M shares +0.56%
Common Stock, Shares, Outstanding 44.4M shares +0.51%
Entity Public Float 377M USD +378%
Common Stock, Value, Issued 280M USD +0.49%
Weighted Average Number of Shares Outstanding, Basic 44.4M shares +0.59%
Weighted Average Number of Shares Outstanding, Diluted 44.3M shares +0.43%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.3M USD -0.24%
General and Administrative Expense 15.2M USD +44.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.23M USD +0.89%
Income Tax Expense (Benefit) 1.6K USD
Net Income (Loss) Attributable to Parent -31.1M USD -20.6%
Earnings Per Share, Basic -0.69 USD/shares -16.9%
Earnings Per Share, Diluted -0.64 USD/shares -6.67%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.3M USD +164%
Assets, Current 122M USD -15.1%
Operating Lease, Right-of-Use Asset 272K USD -25.1%
Assets 123M USD -15.1%
Accounts Payable, Current 1.84M USD -29.4%
Accrued Liabilities, Current 1.16M USD +309%
Liabilities, Current 3.69M USD +4.43%
Operating Lease, Liability, Noncurrent 180K USD -34.6%
Liabilities 3.87M USD +1.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.07M USD +1.35%
Retained Earnings (Accumulated Deficit) -217M USD -16.8%
Stockholders' Equity Attributable to Parent 119M USD -15.6%
Liabilities and Equity 123M USD -15.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.47M USD +4.67%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -3.93M USD -148%
Common Stock, Shares, Issued 44.4M shares +0.51%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.4M USD -733%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 93.3M USD +164%
Deferred Tax Assets, Valuation Allowance 50.3M USD +11.3%
Deferred Tax Assets, Gross 50.3M USD +11.3%
Operating Lease, Liability 305K USD -18.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -31.1M USD -20.5%
Lessee, Operating Lease, Liability, to be Paid 346K USD -23.1%
Operating Lease, Liability, Current 125K USD +25.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 135K USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 131K USD +25.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 41.1K USD -45.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 80.3K USD -40.4%
Deferred Tax Assets, Operating Loss Carryforwards 49.8M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.7K USD
Additional Paid in Capital 57.5M USD +15.7%
Deferred Tax Assets, Net of Valuation Allowance 0 USD